Barr To Co-Promote Kos' Anti-Cholesterol Products Under Settlement
This article was originally published in The Pink Sheet Daily
Executive Summary
Barr's patent litigation settlement with Kos includes a co-promotion agreement for the brand firm's cholesterol-lowering products Niaspan and Advicor
You may also be interested in...
Barr Plans To Boost Generic Oral Contraceptive Through Promotion Of Organon's Mircette
A proposed $155 mil. deal would give Barr the NDA for Organon's oral contraceptive and settle ongoing patent litigation related to Barr's Mircette generic.
Barr Plans To Boost Generic Oral Contraceptive Through Promotion Of Organon's Mircette
A proposed $155 mil. deal would give Barr the NDA for Organon's oral contraceptive and settle ongoing patent litigation related to Barr's Mircette generic.
Barr Scraps Seasonale Ad Revisions, Starts On New DTC Campaign
The company attributes a slowdown in growth for the extended-regimen oral contraceptive to the hiatus in direct-to-consumer advertising. The DTC spots were pulled after FDA objected to the original ad and the revised version. New ads will debut in late spring or early summer, CEO Downey says.